A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: MK-1167; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06625840

1167-004

MK-1167-004 (Other Identifier)

Details and patient eligibility

About

The goal of this study is to learn how safe MK-1167 is in healthy elderly adults and how well people tolerate it.

Enrollment: 16 patients

Sex: All

Ages: 60 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

The main inclusion criteria include but are not limited to the following:

• Be in good health

The main exclusion criteria include but are not limited to the following:

• History of clinically significant endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
• History of cancer (malignancy).

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: Triple Blind

---

16 participants in 2 patient groups

Panel A

Experimental group

Description:

Participants receive a loading dose of MK-1167 or Placebo orally on day 1, followed by a once daily (QD) maintenance dose orally on days 2 to 16.

Treatment:

Drug: Placebo

Drug: MK-1167

Panel B

Experimental group

Description:

Participants receive a loading dose of MK-1167 or Placebo orally on days 1 to 3, followed by a QD maintenance dose orally on days 4 to 16.

Treatment:

Drug: Placebo

Drug: MK-1167